TC
AMAG

TFS Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

TFS Capital’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-55,361
Closed -$1.25M – 840
2017
Q1 		$1.25M Buy
55,361
+8,147
+17% +$195K 0.41% 33
2016
Q4 		$1.64M Sell
47,214
-23,545
-33% -$703K 0.44% 20
2016
Q3 		$1.73M Buy
70,759
+58,844
+494% +$1.47M 0.42% 47
2016
Q2 		$285K Sell
11,915
-26,955
-69% -$618K 0.05% 619
2016
Q1 		$910K Buy
+38,870
New +$923K 0.13% 284
2015
Q4 		– Sell
-48,211
Closed -$1.92M – 993
2015
Q3 		$1.92M Buy
48,211
+28,235
+141% +$1.75M 0.18% 178
2015
Q2 		$1.38M Buy
19,976
+7,068
+55% +$445K 0.13% 253
2015
Q1 		$706K Buy
+12,908
New +$615K 0.07% 439
2014
Q2 		– Sell
-52,253
Closed -$1.01M – 1450
2014
Q1 		$1.01M Buy
52,253
+9,896
+23% +$210K 0.07% 452
2013
Q4 		$1.03M Sell
42,357
-5,474
-11% -$129K 0.05% 544
2013
Q3 		$1.03M Buy
47,831
+4,213
+10% +$99.5K 0.05% 568
2013
Q2 		$971K Buy
+43,618
New +$961K 0.04% 609

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TFS Capital's AMAG Position: Q2 2017 in Review

TFS Capital sold out of AMAG Pharmaceuticals (AMAG) in Q2 2017, closing a stake of 55,361 shares — an estimated $1.25M sold.

TFS Capital first reported a position in AMAG in Q2 2013 and held it in 12 quarters. The position peaked at $1.92M in Q3 2015. 174 funds tracked by Wall St. Rank hold AMAG as of Q2 2017.

  • TFS Capital reported no remaining AMAG Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • TFS Capital sold 55,361 AMAG Pharmaceuticals shares in Q2 2017, an estimated $1.25M.
  • TFS Capital first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • TFS Capital's AMAG Pharmaceuticals position peaked at $1.92M in Q3 2015.
  • 174 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.